Screening and verification of ssDNA aptamers targeting human hepatocellular carcinoma

Acta Biochimica et Biophysica Sinica

Volumn 46, Issue 2, 2014, Pages 128-135

  Lu, Bin ^a   Wang, Jiucun ^b   Zhang, Jun ^a   Zhang, Xiaojiao ^c   Yang, Dongqin ^a   Wu, Lijun ^a   Luo, Zhongguang ^a   Ma, Yanyun ^b   Zhang, Qi ^c   Ma, Yunfang ^a   Pei, Xiaoyu ^a   Yu, Hua ^d   Liu, Jie ^a,c  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

cell imaging; DNA aptamer; drug delivery; liver cancer

Indexed keywords

APTAMER; DNA APTAMER; TUMOR MARKER;

ARTICLE; CELL IMAGING; CELL LINE; CHEMISTRY; COMBINATORIAL CHEMISTRY; DRUG DELIVERY SYSTEM; GENETICS; HEPG2 CELL LINE; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; METHODOLOGY;

CELL IMAGING; DNA APTAMER; DRUG DELIVERY; LIVER CANCER;

APTAMERS, NUCLEOTIDE; CARCINOMA, HEPATOCELLULAR; CELL LINE; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; SELEX APTAMER TECHNIQUE; TUMOR MARKERS, BIOLOGICAL;

EID: 84893336255     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmt130     Document Type: Article

References (23)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61: 69-90.
2. Bruix J and Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 2011, 53: 1020-1022.
3. Schwartz M, Roayaie S and Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 2007, 4: 424-432.
4. Tuerk C and Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249: 505-510.
5. Wu X, Ding BY, Gao J, Wang HY, Fan W, Wang X and Zhang W, et al. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Int J Nanomedicine 2011, 6: 1747-1756.
6. Zhang K, Sefah K, Tang L, Zhao Z, Zhu G, Ye M and Sun W, et al. A novel aptamer developed for breast cancer cell internalization. ChemMedChem 2012, 7: 79-84.
7. Ng EWM, Shima DT, Calias P, Cunningham ET, Guyer DR and Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006, 5: 123-132.
8. Fang XH and Tan WH. Aptamers generated from cell-SELEX for molecular medicine: A chemical biology approach. Acc Chem Res 2010, 43: 48-57.
9. Shangguan D, Li Y, Tang ZW, Cao ZHC, Chen HW, Mallikaratchy P and Sefah K, et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA 2006, 103: 11838-11843.
10. Shangguan D, Meng L, Cao ZC, Xiao Z, Fang X, Li Y and Cardona D, et al. Identification of liver cancer-specific aptamers using whole live cells. Anal Chem 2008, 80: 721-728.
11. Sefah K, Shangguan D, Xiong XL, ODonoghue MB and Tan WH. Development of DNA aptamers using cell-SELEX. Nat Protoc 2010, 5: 1169-1185.
12. Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, Fimmel C and Tennant BC, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci USA 2005, 102: 779-784.
13. Feng JT, Liu YK, Song HY, Dai Z, Qin LX, Almofti MR and Fang CY, et al. Heat-shock protein 27: A potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics 2005, 5: 4581-4588.
14. Harimoto N, Shimada M, Aishima S, Kitagawa D, Itoh S, Tsujita E and Maehara S, et al. The role of heat shock protein 27 expression in hepatocellular carcinoma in Japan: Special reference to the difference between hepatitis B and C. Liver Int 2004, 24: 316-321.
15. Gu YL, Chen WL, Zhao Y, Chen LY and Peng T. Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases. Ann Clin Biochem 2009, 46: 38-43.
16. Wu CC and Yates JR. The application of mass spectrometry to membrane proteomics. Nat Biotechnol 2003, 21: 262-267.
17. Lee HS, Kim C, Kim SB, Kim MG and Park D. Epithin, a target of transforming growth factor-beta signaling, mediates epithelial-mesenchymal transition. Biochem Biophys Res Commun 2010, 395: 553-559.
18. Leong KG and Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood 2006, 107: 2223-2233.
19. Shi H, He XX, Wang KM, Wu X, Ye XS, Guo QP and Tan WH, et al. Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration. Proc Natl Acad Sci USA 2011, 108: 3900-3905.
20. Berezovski MV, Lechmann M, Musheev MU, Mak TW and Krylov SN. Aptamer-facilitated biomarker discovery (AptaBiD). J Am Chem Soc 2008, 130: 9137-9143.
21. Waterston RH, Lindblad-Toh K, Birney E, Rogers J, Abril JF, Agarwal P and Agarwala R, et al. Initial sequencing and comparative analysis of the mouse genome. Nature 2002, 420: 520-562.
22. Schutze T, Arndt PF, Menger M,Wochner A, Vingron M, Erdmann VA and Lehrach H, et al. A calibrated diversity assay for nucleic acid libraries using DiStRO: A diversity standard of random oligonucleotides. Nucleic Acids Res 2010, 38: E23.
23. Zeng ZH, Zhang P, Zhao NX, Sheehan AM, Tung CH, Chang CC and Zu YL. Using oligonucleotide aptamer probes for immunostaining of formalinfixed and paraffin-embedded tissues. Mod Pathol 2010, 23: 1553-1558.